Combination Therapies for Advanced Hepatocellular Carcinoma: Biomarkers and Unmet Needs.

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

The novel combination of checkpoint inhibitors targeting the PD(L)1 pathway and anti-VEGFA therapy has revolutionized the treatment landscape of advanced hepatocellular carcinoma (HCC). However, biomarkers predictive of response to these therapies are still lacking, representing a major clinical challenge. See related articles by Zhang et al., p. 3499, and Zhu et al., p. 3537.

Keyphrases

dna damage
cancer therapy
combination therapy
oxidative stress
drug delivery
cell therapy
smoking cessation